OTC · CIK 0000946486
WINT WINDTREE THERAPEUTICS INC /DE/
Insider trading from SEC Form 4. Last filing Oct 9, 2024. Close $0.00 on Oct 12, 2026, +900% from the 52-week low and -99% from the high.
In brief
WINDTREE THERAPEUTICS INC /DE/ (WINT) has 10 SEC Form 4 filings on file from 5 insiders, the latest filed on Oct 9, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
3 open-market trades have been scored at WINT. The newest: Craig Fraser (President and CEO) bought $4,942 of stock on Oct 8, 2024, filed Oct 9, 2024, scored 53 (moderate).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at WINDTREE THERAPEUTICS INC /DE/, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 53Moderate | Craig Fraser President and CEO buy | $4,942 5,431 shares | +169% | 0% from low-96% from high | |
| 54Moderate | Craig Fraser President and CEO buy | $2,650 1,497 shares | +27% | 0% from low-95% from high | |
| 49Moderate | Craig Fraser President and CEO buy | $2,485 1,315 shares | +31% | 0% from low-95% from high |
Transactions
Every row filed, 19 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 8, 2024 | Craig Fraser President and CEO | POpen-market purchase Common Stock | +5,431 | $0.91 | $4,942 | 8,638 | Oct 9, 2024 |
| Jul 22, 2024 | Craig Fraser President and CEO | AGrant or award Series C Preferred Stockderivative | +19 | - | - | 19 | Jul 24, 2024 |
| Jul 22, 2024 | Steven Simonson SVP, Chief Medical Officer | AGrant or award Series C Preferred Stockderivative | +13 | - | - | 13 | Jul 24, 2024 |
| Jul 22, 2024 | Craig Fraser President and CEO | AGrant or award Warrants (Right to Buy)derivative | +4,011 | - | - | 4,011 | Jul 24, 2024 |
| Jul 22, 2024 | Steven Simonson SVP, Chief Medical Officer | AGrant or award Warrants (Right to Buy)derivative | +2,674 | - | - | 2,674 | Jul 24, 2024 |
| Apr 26, 2023 | Craig Fraser President and CEO | POpen-market purchase Common Stock | +1,497 | $1.77 | $2,650 | 7,010 | Apr 27, 2023 |
| Apr 25, 2023 | Craig Fraser President and CEO | POpen-market purchase Common Stock | +1,315 | $1.89 | $2,485 | 5,513 | Apr 26, 2023 |
| Feb 28, 2023 | Craig Fraser President and CEO | FTax withholding Common Stock | -334 | $0.00 | $0 | 4,198 | Mar 2, 2023 |
| Feb 28, 2023 | Steven Simonson SVP, Chief Medical Officer | FTax withholding Common Stock | -100 | $0.00 | $0 | 1,573 | Mar 2, 2023 |
| Feb 28, 2023 | Eric Curtis SVP & COO | FTax withholding Common Stock | -99 | $0.00 | $0 | 1,253 | Mar 2, 2023 |
| Feb 28, 2023 | Diane Carman SVP & General Counsel | FTax withholding Common Stock | -99 | $0.00 | $0 | 1,227 | Mar 2, 2023 |
| Feb 22, 2023 | James Huang director | XIn-the-money exercise Common Stockindirect: See Footnote | +1,112,308 | $0.14 | $157k | 3,449,161 | Feb 23, 2023 |
| Feb 22, 2023 | James Huang director | DDisposition to issuer Warrants (right to purchase)derivativeindirect: See Footnote | -275,862 | $0.00 | $0 | 0 | Feb 23, 2023 |
| Feb 22, 2023 | James Huang director | DDisposition to issuer Warrants (right to purchase)derivativeindirect: See Footnote | -275,938 | $0.00 | $0 | 0 | Feb 23, 2023 |
| Feb 22, 2023 | James Huang director | DDisposition to issuer Warrants (right to purchase)derivativeindirect: See Footnote | -498,008 | $0.00 | $0 | 0 | Feb 23, 2023 |
| Feb 22, 2023 | James Huang director | DDisposition to issuer Warrants (right to purchase)derivativeindirect: See Footnote | -62,500 | $0.00 | $0 | 0 | Feb 23, 2023 |
| Feb 22, 2023 | James Huang director | AGrant or award Warrants (right to purchase)derivativeindirect: See Footnote | +1,112,308 | $0.00 | $0 | 1,112,308 | Feb 23, 2023 |
| Feb 22, 2023 | James Huang director | XIn-the-money exercise Warrants (right to purchase)derivativeindirect: See Footnote | -1,112,308 | $0.00 | $0 | 0 | Feb 23, 2023 |
| Feb 22, 2023 | James Huang director | AGrant or award Warrants (right to purchase)derivativeindirect: See Footnote | +2,224,616 | $0.00 | $0 | 2,224,616 | Feb 23, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Diane CarmanSVP & General Counsel
- Eric CurtisSVP & COO
- Craig FraserPresident and CEO
- James Huangdirector, owner, ceo, officer
- Steven SimonsonSVP, Chief Medical Officer
Questions about WINT
Answered from the filings on this page, as of the latest one.
Are insiders buying WINT?
No. In the last 90 days no insider at WINDTREE THERAPEUTICS INC /DE/ bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade WINT on the open market?
Craig Fraser (President and CEO) bought $4,942 of WINT on Oct 8, 2024 and filed the Form 4 on Oct 9, 2024. InsiderTell scored 53 (moderate).
How many insiders file Form 4 at WINDTREE THERAPEUTICS INC /DE/?
5 people have filed a Form 4 at WINDTREE THERAPEUTICS INC /DE/, among them Diane Carman (SVP & General Counsel), Eric Curtis (SVP & COO), Craig Fraser (President and CEO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.